Dimensional Fund Advisors LP Boosts Stock Position in LifeStance Health Group, Inc. $LFST

Dimensional Fund Advisors LP grew its holdings in LifeStance Health Group, Inc. (NASDAQ:LFST) by 16.4% during the first quarter, HoldingsChannel.com reports. The firm owned 10,367,680 shares of the company’s stock after acquiring an additional 1,461,215 shares during the quarter. Dimensional Fund Advisors LP’s holdings in LifeStance Health Group were worth $66,038,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Larson Financial Group LLC boosted its position in LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after buying an additional 3,791 shares during the period. KBC Group NV purchased a new stake in shares of LifeStance Health Group in the first quarter valued at approximately $29,000. Bayesian Capital Management LP bought a new position in LifeStance Health Group in the second quarter worth approximately $52,000. Assetmark Inc. increased its holdings in LifeStance Health Group by 17.0% during the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock worth $60,000 after purchasing an additional 1,367 shares during the period. Finally, Krane Funds Advisors LLC bought a new stake in LifeStance Health Group during the 4th quarter valued at $71,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

LifeStance Health Group Trading Down 2.4%

NASDAQ LFST opened at $10.48 on Friday. LifeStance Health Group, Inc. has a 52 week low of $3.74 and a 52 week high of $11.76. The company has a 50 day moving average price of $9.65 and a 200 day moving average price of $7.94. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.18. The firm has a market cap of $4.06 billion, a PE ratio of 174.67 and a beta of 1.12.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.03. The business had revenue of $403.48 million for the quarter, compared to analyst estimates of $387.46 million. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. LifeStance Health Group’s quarterly revenue was up 21.2% compared to the same quarter last year. As a group, sell-side analysts forecast that LifeStance Health Group, Inc. will post 0.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. KeyCorp raised their price target on LifeStance Health Group from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. BTIG Research boosted their price target on shares of LifeStance Health Group from $12.00 to $15.00 and gave the company a “buy” rating in a report on Friday, July 24th. Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. JPMorgan Chase & Co. lifted their price objective on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Finally, The Goldman Sachs Group assumed coverage on LifeStance Health Group in a report on Friday, June 5th. They set a “neutral” rating and a $9.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $11.50.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, Director Darren M. Black sold 5,899,661 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total transaction of $47,315,281.22. Following the sale, the director owned 23,310,115 shares of the company’s stock, valued at approximately $186,947,122.30. The trade was a 20.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Eric Shuey sold 243,362 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $1,951,763.24. Following the completion of the transaction, the director directly owned 867,562 shares of the company’s stock, valued at approximately $6,957,847.24. This represents a 21.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 7,687,394 shares of company stock valued at $63,579,701 in the last ninety days. Corporate insiders own 3.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.